Book Value per Share: Amicus Therapeutics Inc (FOLD)

Graphic logo of Amicus Therapeutics (FOLD)

The visualization of Amicus Therapeutics (FOLD) market value on the GURU.Markets platform confirms the resilience of a business protected by insurmountable patent barriers and strict FDA oversight. Amicus Therapeutics (FOLD) revenues are based on the commercialization of advanced therapies for Pompe and Fabry diseases, with the indicator standing at 0.88. The nature of rare pathologies renders demand independent of market cycles, tying success to clinical trial results.

Amicus Therapeutics Inc (FOLD): Share Book Value from 07/04/2022 to 05/09/2026

amicusrx.com - analytical breakdowns and key metrics (FOLD)

- price and consensus price forecast:
Price Chart Amicus Pharma|FOLD - Price Target Chart
- market capitalization data:
Market Capitalization Amicus Therapeutics, Inc.|FOLD - Business Value
- book capitalization data:
Net Assets per Single Share Amicus Therapeutics|FOLD - Net Asset Value|Market Capitalization to Book Value Ratio amicusrx.com|FOLD - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Amicus Therapeutics|FOLD - Long-Term Debt to Capital|Short-Term Debt to Equity Amicus Therapeutics, Inc.|FOLD - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Amicus Therapeutics, Inc.
Fundamental company valuation:Amicus Pharma - FOLD
Manufactured products of Amicus Therapeutics, Inc.

Amicus Therapeutics (FOLD) is developing costly gene therapies for rare diseases, which requires significant capital expenditures. The book value per share, calculated under US GAAP as the difference between assets and liabilities per share, determines the intrinsic value of the business. The current BVPS stands at 0.88, reflecting the company's actual equity. The trend of this metric allows for an assessment of asset quality beyond market euphoria. Growth in this metric confirms financial stability during expansion within the orphan drug segment.

Competitors of Amicus Therapeutics (FOLD)

ASND - Net Assets per Single Share|MDGL - Net Assets per Single Share|Book Value per Share Corcept Therapeutics|RYTM (rhythmtx.com) - Equity per Share|Net Assets per Single Share Akero AKRO|Share Book Value Metsera, Inc.|MoonLake Pharma (MLTX) - Book Value per Share|Accounting Value of a Share Crinetics Corp (CRNX)|Book Value per Share NAMS (NewAmsterdam Pharma)|soleno.life - Book Value per Share|Net Assets per Single Share 89bio (ETNB)|AGIO: Accounting Value of a Share|GPCR (Structure Pharma) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS